Back
 OJCD  Vol.7 No.1 , March 2017
Motor Development as a Potential Marker to Monitor Infantile Pompe Disease on Enzyme Replacement Therapy
Abstract: After Enzyme Replacement Therapy (ERT) using recombinant human acid alpha-glucosidase (rhGAA), survival of Infantile Pompe Disease (IPD) patients through the first 18 months of age has been documented and acquisitions of motor development are an important outcome, but description of its course is scarce. Objective: To describe the motor development in an IPD patient and its correlation with clinical conditions during the first 18 months on ERT with rhGAA. Methods: By longitudinal observational study of an IPD case at early stage. Clinical and biochemical characteristics were obtained from patient records. Echocardiogram assessed cardiac indexes and the urinary biomarker—glucose tetrasaccharide (Glc4)—was obtained by HPLC/UV, following sample derivatization with butyl 4-amino benzoate and analysis on a C18 stationary phase column. Motor skills were evaluated with Alberta Infant of Motor Scale (AIMS) and motor delay was considered as motor percentile (p) below 10. Descriptive statistical analysis was carried out and t-test was used to calculate the differences among means, with significance level defined as p value < 0.05. Results: After ERT beginning amelioration of the cardiomyopathy with reduced left ventricle mass index (LVMI) from the 2nd month onwards was observed, but above the upper normal limit for healthy children and CRIM-positive IPD patients. Although GAA antibodies level remained above the recommended titers and fluctuating elevation of Glc4 quantified, motor development analysis showed an ascendant curve expected for age within achievement of independent ambulation. Motor delay after pneumonia and maintenance of hypotonia were noted. Variation of Glc4 appeared long after a transitory intercurrence. Conclusion: In an IPD case, motor development can have normal evolution despite hypotonia. Motor analysis seems to be sensitive to follow-up clinical intercurrences. To elucidate the interaction among prognostic factors and outcomes, further clinical studies need to be conducted.
Cite this paper: de Almeida Thomazinho, P. , Scalco, F. , de Oliveira, M. , Horovitz, D. and Llerena Jr., J. (2017) Motor Development as a Potential Marker to Monitor Infantile Pompe Disease on Enzyme Replacement Therapy. Open Journal of Clinical Diagnostics, 7, 8-19. doi: 10.4236/ojcd.2017.71002.
References

[1]   Hirschhorn, R. and Reuser, A.J.J. (2001) Glycogen Storage Disease Type II: Acid Alphaglucosidase (Acid Maltase) Deficiency. In: Scriver, C.R., Beaudet, A.L., Sly, W.S. and Valle, M.D., Eds., The Metabolic and Molecular Bases of Inherited Disease, McGraw-Hill, New York, 3389-3420.

[2]   U.S. Food and Drug Administration (2006) First Treatment for Pompe Disease. FDA Consumer Magazine, 2-3.

[3]   Kishnani, P.S., Beckemeyer, A.A. and Mendelsohn, N.J. (2012) The New Era of Pompe Disease: Advances in the Detection, Understanding of the Phenotypic Spectrum, Pathophysiology, and Management. American Journal of Medical Genetics Part C: Seminars in Medical Genetics, 160C, 1-7.
https://doi.org/10.1002/ajmg.c.31324

[4]   Chien, Y.-H., Lee, N.-C., Thurberg, B.L., Chiang, S.-C., Zhang, X.K., Keutzer, J., et al. (2009) Pompe Disease in Infants: Improving the Prognosis by Newborn Screening and Early Treatment. Pediatrics, 124, e1116-e1125.
https://doi.org/10.1542/peds.2008-3667

[5]   Howell, R.R., Byrne, B., Darras, B.T., Kishnani, P., Nicolino, M. and van der Ploeg, A. (2006) Diagnostic Challenges for Pompe Disease: An Under-Recognized Cause of Floppy Baby Syndrome. Genetics in Medicine, 8, 289-296.
https://doi.org/10.1097/01.gim.0000204462.42910.b8

[6]   Kishnani, P.S., Hwu, W.-L., Mandel, H., Nicolino, M., Yong, F. and Corzo, D. (2006) A Retrospective, Multinational, Multicenter Study on the Natural History of Infantile-Onset Pompe Disease. Journal of Pediatrics, 148, 671-676.
https://doi.org/10.1016/j.jpeds.2005.11.033

[7]   Kishnani, P.S., Steiner, R.D., Bali, D., Berger, K., Byrne, B.J., Case, L.E., et al. (2006) Pompe Disease Diagnosis and Management Guideline. Genetics in Medicine, 8, 267-288.
https://doi.org/10.1097/01.gim.0000218152.87434.f3

[8]   Chien, Y.-H., Lee, N.-C., Chen, C.-A., Tsai, F.-J., Tsai, W.-H., Shieh, J.-Y., et al. (2015) Long-Term Prognosis of Patients with Infantile-Onset Pompe Disease Diagnosed by Newborn Screening and Treated since Birth. Journal of Pediatrics, 166, 985-991.
https://doi.org/10.1016/j.jpeds.2014.10.068

[9]   Prater, S.N., Patel, T.T., Buckley, A.F., Mandel, H., Vlodavski, E., Banugaria, S.G., et al. (2013) Skeletal Muscle Pathology of Infantile Pompe Disease during Long-Term Enzyme Replacement Therapy. Orphanet Journal of Rare Diseases, 8, 90.
https://doi.org/10.1186/1750-1172-8-90

[10]   Llerena, J.C., Horovitz, D.M., Nagahashi Marie, S.K., Porta, G., Giugliani, R., Munoz Rojas, M.V., et al. (2009) The Brazilian Consensus on the Management of Pompe Disease. Journal of Pediatrics, 155, S47-S56.
https://doi.org/10.1016/j.jpeds.2009.07.006

[11]   Savegnago, A.K., da Silva, R.M., Jonhston, C., Martins, A.M., Melo, A.P.L., Carvalho, W.B., et al. (2012) Systematic Review of Functional Assessment Scales in Pompe Disease. Revista Paulista de Pediatria, 30, 272-277.
https://doi.org/10.1590/S0103-05822012000200018

[12]   Piper, M.C. and Darrah, J. (1994) Motor Assessment of the Developing Infant. United States. WB Saunders Company, Philadelphia, 210 p.

[13]   Aerts, J., Kallemeijn, W.W., Wegdam, W., Joao Ferraz, M., van Breemen, M.J., Dekker, N., et al. (2011) Biomarkers in the Diagnosis of Lysosomal Storage Disorders: Proteins, Lipids, and Inhibodies. Journal of Inherited Metabolic Disease, 34, 605-619.
https://doi.org/10.1007/s10545-011-9308-6

[14]   Suomalainen, A. (2011) Biomarkers for Mitochondrial Respiratory Chain Disorders. Journal of Inherited Metabolic Disease, 34, 277-282.
https://doi.org/10.1007/s10545-010-9222-3

[15]   Young, S.P., Zhang, H., Corzo, D., Thurberg, B.L., Bali, D., Kishnani, P.S., et al. (2009) Long-Term Monitoring of Patients with Infantile-Onset Pompe Disease on Enzyme Replacement Therapy Using a Urinary Glucose Tetrasaccharide Biomarker. Genetics in Medicine, 11, 536-541.
https://doi.org/10.1097/GIM.0b013e3181a87867

[16]   Young, S.P., Piraud, M., Goldstein, J.L., Zhang, H., Rehder, C., Laforet, P., et al. (2012) Assessing Disease Severity in Pompe Disease: The Roles of a Urinary Glucose Tetrasaccharide Biomarker and Imaging Techniques. American Journal of Medical Genetics Part C: Seminars in Medical Genetics, 160C, 50-58.
https://doi.org/10.1002/ajmg.c.31320

[17]   An, Y., Young, S.P., Kishnani, P.S., Millington, D.S., Amalfitano, A., Corzo, D., et al. (2005) Glucose Tetrasaccharide as a Biomarker for Monitoring the Therapeutic Response to Enzyme Replacement Therapy for Pompe Disease. Molecular Genetics and Metabolism, 85, 247-254.
https://doi.org/10.1016/j.ymgme.2005.03.010

[18]   Vogel, M., Staller, W. and Bühlmeyer, K. (1991) Left Ventricular Myocardial Mass Determined by Cross-Sectional Echocardiography in Normal Newborns, Infants, and Children. Pediatric Cardiology, 12, 143-149.
https://doi.org/10.1007/BF02238520

[19]   Kroos, M., Hoogeveen-Westerveld, M., van der Ploeg, A. and Reuser, A.J. (2012) The Genotype-Phenotype Correlation in Pompe Disease. American Journal of Medical Genetics Part C: Seminars in Medical Genetics, 160C, 59-68.
https://doi.org/10.1002/ajmg.c.31318

[20]   Kishnani, P.S., Goldenberg, P.C., DeArmey, S.L., Heller, J., Benjamin, D., Young, S., et al. (2010) Cross-Reactive Immunologic Material Status Affects Treatment Outcomes in Pompe Disease Infants. Molecular Genetics and Metabolism, 99, 26-33.
https://doi.org/10.1016/j.ymgme.2009.08.003

[21]   Banugaria, S.G., Prater, S.N., Ng, Y.-K., Kobori, J.A., Finkel, R.S., Ladda, R.L., et al. (2011) The Impact of Antibodies on Clinical Outcomes in Diseases Treated with Therapeutic Protein: Lessons Learned from Infantile Pompe Disease. Genetics in Medicine, 13, 729-736.
https://doi.org/10.1097/GIM.0b013e3182174703

[22]   Pereira, S.J. and Berditchevisky, C.R. (2008) Report of the First Brazilian Infantile Pompe Disease Patient to Be Treated with Recombinant Human Acid Alpha-Glucosidase. Journal of Pediatrics, 84, 272-275.

[23]   Prater, S.N., Banugaria, S.G., DeArmey, S.M., Botha, E.G., Stege, E.M., Case, L.E., et al. (2012) The Emerging Phenotype of Long-Term Survivors with Infantile Pompe Disease. Genetics in Medicine, 14, 800-810.
https://doi.org/10.1038/gim.2012.44

[24]   Case, L.E., Beckemeyer, A.A. and Kishnani, P.S. (2012) Infantile Pompe Disease on ERT—Update on Clinical Presentation, Musculoskeletal Management, and Exercise Considerations. American Journal of Medical Genetics Part C: Seminars in Medical Genetics, 160C, 69-79.
https://doi.org/10.1002/ajmg.c.31321

[25]   Matsunaga, E.M. (2009) Muscle Fiber Type Distribution and Genotype Correlation in the Pompe Disease. Dissertacao, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo.

[26]   van den Berg, L.E.M., Drost, M.R., Schaart, G., de Laat, J., van Doorn, P.A., van der Ploeg, A.T., et al. (2013) Muscle Fiber-Type Distribution, Fiber-Type-Specific Damage, and the Pompe Disease Phenotype. Journal of Inherited Metabolic Disease, 36, 787-794.
https://doi.org/10.1007/s10545-012-9541-7

[27]   Raben, N., Danon, M., Gilbert, A.L., et al. (2003) Enzyme Replacement Therapy in the Mouse Model of Pompe Disease. Molecular Genetics and Metabolism, 8, 156-169.
https://doi.org/10.1016/j.ymgme.2003.08.022

[28]   Darrah, J., Senthilselvan, A. and Magill-Evans, J. (2009) Trajectories of Serial Motor Scores of Typically Developing Children. Infant Behavior & Development, 32, 72-78.
https://doi.org/10.1016/j.infbeh.2008.10.001

[29]   Council on Children with Disabilities, Section on Developmental Behavioral Pediatrics (2006) Identifying Infants and Young Children with Developmental Disorders in the Medical Home: An Algorithm for Developmental Surveillance and Screening. Pediatrics, 118, 405-720.
https://doi.org/10.1542/peds.2006-1231

 
 
Top